High efficacy of primary chemoprophylaxis with primaquine. Metanalysis;La primaquina tiene alta eficacia en la quimioprofilaxis primaria simple antipalúdica. Metanálisis

Iatreia

Volumn 19, Issue 3, 2006, Pages 244-260

  Carmona Fonseca, Jaime ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

Falciparum; Malaria; Meta analysis; Paludism; Plasmodium; Primaquine; Primary prophylaxis; Vivax

Indexed keywords

PRIMAQUINE;

ARTICLE; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; HUMAN; MALARIA; META ANALYSIS; PLASMODIUM; SYSTEMATIC REVIEW;

EID: 33845452178     PISSN: 01210793     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Jenicek M, Cléroux R. Epidemiología: principios, técnicas, aplicaciones. Barcelona: Salvat; 1987.
2. Milhous W. Development of new drugs for chemoprophylasis of malaria. Bull Soc Path Exotique 2001; 94:149-151.
3. Chen LH, Keystone JS. New strategies for the prevention of malaria in travelers. Infec Dis Clin N Am 2005; 19: 185-210.
4. Patel SN, Kain KC. Atovaquone/proguanil for the prophylaxis and treatment of malaria. Expert Rev Anti-infective Ther 2005; 3: 849-861.
5. Grewal RS. Pharmacology of 8-aminoquinolines. Bull World Health Org 1981; 59: 397-406.
6. a ed. Buenos Aires: El Ateneo; 1988: capítulo 51 (Quimioterapia del paludismo y de la toxoplasmosis. Drogas antipalúdicas supresivas y curativas. Drogas activas en la toxoplasmosis): 794-805.
7. Teklehaimanot A, Nguyen-Dinh P, Collins WE, Barber AM, Campbell CC. Evaluation of sporontocidal compounds using Plasmodium falciparum gametocytes produced in vitro. Am J Trop Med Hyg 1985; 34: 429-434.
8. Ponsa N, Sattabongkot J, Kittayapong P, Eikarat N, Coleman RE. Transmission-blocking activity of tafenoquine (WR-238605) and artelinic acid against naturally circulating strains of Plasmodium vivax in Thailand. Am J Trop Med Hyg 2003; 69: 542-547.
9. Coleman RE, Nath AK, Schneider I, Song GH, Klein TA, Milhous WK. Prevention of sporogony of Plasmodium falciparum and P. berghei in Anopheles stephensi mosquitoes by transmission-blocking antimalarials. Am J Trop Med Hyg 1994; 50: 646-653.
10. Rastogi M, Pal NL, Sen AB. Gametocytocidal and sporontocidal activity of some standard antimalarials on P. berghei (NK 65) infection M. natalensis. Indian J Malariol 1989; 26: 9-18.
11. Portela MJ, Moreira R, Valente E, Constantino L, Iley J, Pinto J, et al. Dipeptide derivatives of primaquine as transmission-blocking antimalarials: effect of aliphatic side-chain acylation on the gametocytocidal activity and on the formation of carboxyprimaquine in rat liver homogenates. Pharmacol Res 1999; 16: 949-955.
12. Shao BR, Ye XY. Tissue schizontocidal effect of trifluoroacetyl primaquine in Plasmodium yoelii infected mice and Plasmodium cynomolgi infected monkeys. Southeast Asian J Trop Med Public Health 1991; 22: 81-83.
13. López-Antuñano FJ. Is primaquine useful and safe as true exo-erythrocytic meronticidal, hyponociticial and gametocidal antimalarial drugs? Salud Pública México 1999; 41: 410-419.
14. Gogtay NJ, Chogle AR, Sorabjee JS, Marathe SN, Kshirsagar NA. Poor gametocytocidal activity of 45 mg primaquine in chloroquine-treated patients with acute, uncomplicated, P. falciparum malaria in Mumbai (Bombay): an issue of public-health importance. Ann Trop Med Parasitol 1999; 93: 813-816.
15. Chomcharn Y, Surathin K, BunnaG D, Sucharit S, Harinasuta T. Effect of a single dose of primaquine on a Thai strain of Plasmodium falciparum. Southeast Asian J Trop Med Public Health 1080:11: 408-412.
16. Kaneko A, Kamei K, Suzuki T, Ishii A, Siagian R, Panjaitan W. Gametocytocidal effect of primaquine in a chemotherapeutic malaria control trial in North Sumatra, Indonesia. Southeast Asian J Trop Med Public Health 1989; 20: 351-359.
17. ORGANIZACIÓN MUNDIAL DE LA SALUD (OMS). Comité de expertos de la OMS en paludismo. 20 informe, 2000. Ginebra, OMS, 2000. p. 46-47.
18. Kain KC, Shanks GD, Keystone JS. Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens. Clin Infect Dis 2001; 33: 226-234.
19. Blair S, Lacharme L, Carmona-Fonseca J, Tobón A. Resistencia de Plasmodium falciparum a tres fármacos antimaláricos en Turbo (Antioquia, Colombia), 1998. Rev Panam Salud Pública 2001; 9: 23-29.
20. Blair-Trujillo S, Lacharme-Lora L, Carmona-Fonseca J. Resistance of Plasmodium falciparum to antimalarial drugs in Zaragoza (Antioquia, Colombia), 1998. Mem Inst Oswaldo Cruz 2002; 97: 401-406.
21. Blair S, Tobón A, Echeverri M, Álvarez G, Carmona-Fonseca J. Adecuada respuesta clínica y parasitológica de Plasmodium vivax a la cloroquina en Colombia (Turbo, Antioquia), 2001. Infectio 2002; 6: 21-26.
22. WORLD HEALTH ORGANIZATION (WHO). Assessment and monitoring of antimalarial drugs efficacy for the treatment of uncomplicated falciparum. Geneva, WHO, 2003. WHO/HTM/RBM/2003.50
23. Baird JK, Rieckmann KH. Can primaquine therapy for vivax malaria be improved? Trends Parasitol 2003; 19: 115-120.
24. Collins WE, Jeffery GM. Primaquine resistance in Plasmodium vivax. Am J Trop Med Hyg 1996; 55: 243-249.
25. Duarte EC, Pang LW, Ribeiro LC, Fontes CJ. Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria. Am J Trop Med Hyg 2001; 65: 471-476.
26. Schwartz E, Regev-Yochay G, Kurnik D. Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. Am J Trop Med Hyg 2000; 63: 393-395.
27. Signorini L, Matteelli A, Castelnuovo F, Castelli F, Oladeji O, Carosi G. Short report: primaquine-tolerant P. vivax in an Italian traveler from Guatemala. Am J Trop Med Hyg 1996; 55: 472-473.
28. Baird JK. Effectiveness of antimalarial drugs. New EnglJ Med 2005; 1565-1577.
29. Comment in: New Engl J Med 2005; 353: 420-422; author reply 420-422.
30. Arnold J, Alving A S, Clayman CB. Induced primaquine resistance in vivax malaria. Trans R Soc Trop Med Hyg 1961; 55: 345-350.
31. Cooper WC, Myatt AV, Hernundez T, Jeffrey GM, Coamey GR. Studies on human malaria. XXX. Comparison of primaquine, isopentaquine, SN-3883 and pamaquine as curative agents against sporozoite-induced Chesson strain vivax malaria. Am J Trap Med Hyg 1953; 2: 949-957.
32. Black RH. Malaria in refugees from Indochina as seen in Australia in 1980. Med J Aust 1981; 2: 324-325.
33. Whitby M. Drug resistant Plasmodium vivax malaria. J Antimicrob Chemother 1997; 40: 749-752.
34. Duarte EC; Pang L, Fontes CJF. Validade interna de ensaios terapêuticos em malária: anélise de estudos de avaliação da emergência de resistência in vivo do Plasmodium vivax a doses padronizadas de primaquina. Rev Soc Bras Med Trop 2003; 36: 383-386.
35. Ruebush TK, Zegarra J, Cairo J, Andersen EM, Green M, Pillai DR, et al. Chloroquine-resistant Plasmodium vivax malaria in Peru. Am J Trop Med Hyg 2003; 69: 548-552.
36. Bray PG, Deed S, Fox E, Kalkanidis M, Mungthin M, Deady LW, Tilley L. Primaquine synergises the activity of chloroquine against chloroquine-resistant P. falciparum. Biochem Pharmacol 2005; 70: 1158-1166.
37. Edgcomb JH. Primaquine, SN 13272, a new curative agent in vivax malaria: a preliminary report. J Natl Malaria Soc 1950; 9: 285-292.
38. Alving AS, Arnold J, Hockwald RS, Clayman CB, Dern RJ, Beutler E, Flanagan CL. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med 1995; 46: 301-306.
39. Thacker SB. Metanálisis: un enfoque cuantitativo para la integración de investigaciones. Bol Of Sanit Panam 1993; 115: 328-339.
40. Molinero LM. Meta-análisis [sitio de internet]. Asociación de la Sociedad Española de Hipertensión: Liga Epañola para la lucha contra la Hipertensión Arterial.http://www.seh-lelha.org/ metaanalisis.htm#TOP. Consulta: 5 mar 2005.
41. Cook DJ, Mulrow CD, Haynes RB. Synthesis of best evidence for clinical decisions. Ann Intern Med 126:376-380, 1997.
42. Letón-Molina E, Pedromingo-Marino A. Introducción al análisis de datos en meta-análisis. Madrid: Ed. Díaz De Santos; 2001.
43. Rodríguez MA. Entendiendo los diagramas Odds-Ratio de las revisiones sistemáticas. Rev CES Medicina 2002; 16: 66-72.
44. Manrique RD. El metaanálisis: consideraciones sobre su aplicación. Rev CES Medicina 2002; 16:55-65.
45. CENTRO COCHRANE IBEROAMERICANO. Las revisiones de la literatura científica [sitio en internet]. Curso de Revisiones Sistemáticas. http://www.cochrane.es/Cursos/RevSys. Consulta: 13 sep 2005.
46. Borenstein M, Rothstin H. Comprehensive Meta-Analysis 1.0.25. A computer program for research synthesis. Englewood (NJ, USA), Biostat, 1999.
47. Primo J. Metaanálisis. Versión 26-9-2002 [sitio en internet]. CASP España. Unidad de Digestivo, Hospital de Sagunto. http://www.redcaspe.org/herramientas/hojas.asp. Consulta: 1 oct 2005.
48. Galappaththy GN, Omari AA. Primaquine for preventing relapses in people with Plasmodium vivax malaria (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 3, 2003. Oxford: Update Software.
49. Baird JK, Fryauff DJ, Hoffmann SL. Primaquine for prevention of malaria in travelers. Clin Infect Dis 2003; 37: 1659-1667.
50. Arnold J, Alving AS, Hockwald RS, Clayman CB, Dern RJ, Beutler E, Jeffery GM. The effect of continuous and intermittent primaquine therapy on the relapse rate of Chesson strain vivax malaria. J Lab Clin Med 1954; 44: 429-438.
51. Arnold J, alving AS, Hockwald RS, Clayman CB, Dern RJ, Beutler E, et al. The antimalarial action of primaquine against the blood and tissue stages of falciparum malaria (Panama, P-F-6 strain). J Lab Clin Med 1955; 46: 391-397.
52. th International Congress of Tropical Medicine and Malaria 1959; 7: 203-209.
53. Powell RD, Brewer GJ. Effects of pyrimethamine, chlorguanide, and primaquine against exoerythrocytic forms of a strain of chloroquine-resistant Plasmodium falciparum from Thailand. Am J Trop Med Hyg 1967; 16: 693-698.
54. Baird JK, Fryauff DJ, Basri H, Bangs MJ, Subianto B, Wiady I, et al. Primaquine for prophylaxis against malaria among nonimmune transmigrants in Irian Jaya, Indonesia. Am J Trop Med Hyg 1995; 52: 479-84.
55. Fryauff DJ, Baird JK, Basri H, Sumawinata I, Purnomo, Richie TL, et al. Randomised placebo-controlled trial of primaquine for prophylaxis of falciparum and vivax malaria. Lancet 1995; 346: 1190-1193.
56. Weiss WR, Oloo AJ, Johnson A, Koech D, Hoffman SL. Daily primaquine is effective for prophylaxis against falciparum malaria in Kenya: comparison with mefloquine, doxycycline, and chloroquine plus proguanil. J Infect Dis 1995; 171: 1569-1575.
57. Comentario en: J Infect Dis 1996; 173: 275-276.
58. Soto J, Toledo J, Rodriquez M, Sanchez J, Herrera R, Padilla J, et al. Primaquine prophylaxis against malaria in nonimmune Colombian soldiers: efficacy and toxicity. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 129: 241-244.
59. Comentario en: Ann Intern Med 1999; 130 (6): 536.
60. Respuesta del autor: Ann Intern Med 1999; 130: 536-537.
61. Soto J, Toledo J, Rodriquez M, Sanchez J, Herrera R, Padilla J, Berman J. Double-blind, randomized, placebo-controlled assessment of chloroquine/ primaquine prophylaxis for malaria in nonimmune Colombian soldiers. Clin Infect Dis 1999; 29: 199-201.
62. Schwartz E, Regev-Yochay G. Primaquine as prophylaxis for malaria for monimmune travelers: a comparison with mefloquine and doxycycline. Clin Infect Dis 1999; 29: 1502-1506.
63. Baird JK, Lacy MD, Basri H, Barcus MJ, Maguire JD, Bangs MJ, et al. Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis 2001; 33: 1990-1997.
64. Carmona-Fonseca J. Profilaxis primaria con primaquina para el paludismo: revisión. Anuario Enfermedades Infecciosas (Medellín) 2005; 2: 51-84.
65. Clayman CB, Arnold J, Hochwald RS, Yount EH, Edgcomb JH, Alving AS. Toxicity of primaquine in CaucasianS. JAMA 1952; 149: 1563-1568.
66. Giao PT, DE Vries PJ. Pharmacokinetic interactions of antimalarial agents. Clin Pharmacokinet 2001; 40: 343-373.
67. Guzmán V, Carmona-Fonseca J. Citocromo P450 y respuesta terapéutica antimalárica. Rev Panam Salud Publica 2006;19: 9-22.
68. Li XQ, BJorkman A, Andersson TB, Gustafsson LL, Masimirembwa CM. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Europ J Clin Pharmacol 2003; 59: 429-442.